文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

CYD-TDV登革热疫苗预接种筛查策略会议报告

Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: A meeting report.
PubMed 文献 · Vaccine · 2019-07-31

全球登革热与伊蚊传播疾病联盟于2019年1月召开为期3天的研讨会,亚洲和拉美国家代表讨论CYD-TDV(Dengvaxia)预接种筛查策略的实施挑战。会议强调筛查试验需高特异性以降低个体风险、高灵敏度以最大化个体和群体获益,血清流行率依赖的阳性预测值是评估安全性的最佳指标。

要点

  • CYD-TDV对血清阳性者有效,但血清阴性者首剂后约两年重症登革热风险增加。
  • WHO推荐预接种筛查策略,仅对有既往登革热感染证据者接种。
  • 筛查试验需高特异性降低个体风险、高灵敏度最大化个体和群体获益。

核心结论

  • CYD-TDV对血清阳性者有效但增加血清阴性者重症登革热风险,预接种筛查策略面临诸多实施挑战。
  • 血清流行率依赖的阳性预测值是评估预接种筛查策略可接受安全性的最佳指标。

研究设计与样本

  • 全球登革热与伊蚊传播疾病联盟于2019年1月组织为期3天的研讨会,亚洲和拉美国家代表参加。

主要发现

  • CYD-TDV对血清阳性者有效,但血清阴性者首剂后约两年重症登革热风险增加。
  • 引入Dengvaxia面临筛查试验特性、检测成本联合3剂次程序、后勤、高覆盖率、疫苗信心和沟通等挑战,多于其他疫苗引入规划。
  • 解决Dengvaxia学校接种引入瓶颈也将有利于HPV疫苗及破伤风、百日咳加强剂次等其他疫苗。
  • 公众信任水平高度可变且因情境而异,理解人群认知和关切对定制干预、监测和缓解风险至关重要。

关键数值与推荐

  • WHO推荐预接种筛查策略,仅对有既往登革热感染证据者接种CYD-TDV。
  • 筛查试验需高特异性以最小化个体风险,同时高灵敏度以最大化个体和群体获益。

临床怎么用

  • 政策制定者需考虑基于筛查试验的接种策略的风险-获益、引入疫苗的最佳年龄、沟通和实施策略。
  • 需理解人群认知和关切以定制干预措施、监测并缓解风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The first licensed dengue vaccine, CYD-TDV (Dengvaxia) is efficacious in seropositive individuals, but increases the risk for severe dengue in seronegative persons about two years after administration of the first dose. For countries considering the introduction of Dengvaxia, WHO recommends a pre-vaccination screening strategy whereby only persons with evidence of a past dengue infection would be vaccinated. Policy-makers need to consider the risk-benefit of vaccination strategies based on such screening tests, the optimal age to introduce the vaccine, communication and implementation strategies. To address these questions, the Global Dengue and Aedes-transmitted diseases Consortium (GDAC) organized a 3-day workshop in January 2019 with country representatives from Asia and Latin America. The meeting discussions highlighted many challenges in introducing Dengvaxia, in terms of screening test characteristics, costs of such tests combined with a 3-dose schedule, logistics, achieving high coverage rates, vaccine confidence and communication; more challenges than for any other vaccine introduction programme. A screening test would require a high specificity to minimize individual risk, and at the same time high sensitivity to maximize individual and population benefit. The underlying seroprevalence dependent positive predictive value is the best indicator for an acceptable safety profile of a pre-vaccination screening strategy. The working groups discussed many possible implementation strategies. Addressing the bottlenecks in school-based vaccine introduction for Dengvaxia will also benefit other vaccines such as HPV and booster doses for tetanus and pertussis. Levels of public trust are highly variable and context specific, and understanding of population perceptions and concerns is essential to tailor interventions, monitor and mitigate risks.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wilder-Smith A, Smith PG, Luo R, et al. Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: A meeting report. Vaccine. 2019. PMID: 31377079. doi:10.1016/j.vaccine.2019.07.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。